Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | NEK2 | P51955 | 6/20 | 0.45 |
| ▸ | PLK1 | P53350 | 4/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | HCK | P08631 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200252 | 0.89 | MAPT (0.46) | KDRCSF1RNEK2PLK1BRAF | |
| SCHEMBL2202269 | 0.85 | RORC (0.52) | KDRAURKAAURKBNEK2PLK1 | |
| SCHEMBL2201384 | 0.85 | KDR (0.47) | KDRAURKAAURKBNR2E1ROCK2 | |
| SCHEMBL2202608 | 0.80 | CSF1R (0.45) | KDRCSF1RNEK2PLK1BRAF | |
| SCHEMBL2201594 | 0.80 | BRAF (0.43) | KDRCSF1RNEK2PLK1BRAF | |
| SCHEMBL1408282 | 0.79 | KDR (0.47) | KDRAURKAAURKBNEK2PLK1 | |
| SCHEMBL2201767 | 0.79 | KDR (0.48) | KDRAURKAAURKBLCKROCK2 | |
| SCHEMBL1408536 | 0.78 | AURKA (0.74) | KDRAURKAAURKBNR2E1 | |
| SCHEMBL2202246 | 0.78 | AURKA (0.49) | KDRAURKAAURKBCSF1RNR2E1 | |
| SCHEMBL2200833 | 0.77 | AURKA (0.52) | KDRAURKAAURKBNR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | claimed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | KDR 110/4885AURKA 148/4885AURKB 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.